Vaxcyte CFO Sells Shares for Tax Obligations Amid Strong Share Performance
Andrew Guggenhime, President and CFO of Vaxcyte (NASDAQ:PCVX), recently reported the disposition of 2,705 shares to satisfy tax obligations following the vesting of restricted stock units. The transaction was not a discretionary sale but an automatic transfer upon vesting. Post-transaction, he holds approximately 164,321 total shares valued at $10.12 million as of September 2 market close. Vaxcyte continues to operate with no revenue and reported a net loss of -$1.1 billion in the trailing twelve months (TTM), despite holding $2.51 billion in cash and investments by June 30, up from $2.44 billion at year-end 2025. The company's shares have appreciated significantly over the past year with a return of +95%, driven largely by investor confidence in its clinical pipeline for next-generation vaccines. The firm is focused on developing protein-based vaccines like VAX-24, targeting bacterial infectious diseases and aiming to secure licensing partnerships with pharmaceutical companies. The CFO's insider activity does not signal immediate financial distress but highlights the ongoing need for strategic financing as it advances through clinical trials.
Tickers: $PCVX